Trial ID or NCT#



recruiting iconRECRUITING


This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination (Combo), compared to placebo (cell-free Plasmalyte-A medium) as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.

Official Title

A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF

Eligibility Criteria

Ages Eligible for Study: 21 Years to 79 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Phillip C. Yang, MD
Phillip C. Yang, MD
Professor of Medicine (Cardiovascular Medicine)

Contact us to find out if this trial is right for you.


Fouzia Khan
(650) 736-1410